Participant flow

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · Source last updated 2026-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle

   id

   FG000

   title

   Belantamab Mafodotin

2. description

   Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)

   id

   FG001

   title

   Pomalidomide Plus Dexamethasone

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         1

      type

      Lost to Follow-up

   2. reasons

      1. group Id

         FG000

         num Subjects

         51

      2. group Id

         FG001

         num Subjects

         26

      type

      Physician Decision

   3. reasons

      1. group Id

         FG000

         num Subjects

         22

      2. group Id

         FG001

         num Subjects

         9

      type

      Withdrawal by Subject

   4. reasons

      1. group Id

         FG000

         num Subjects

         15

      2. group Id

         FG001

         num Subjects

         3

      type

      Ongoing at the time of analysis

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         218

      2. group Id

         FG001

         num Subjects

         107

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         217

      2. group Id

         FG001

         num Subjects

         102

      comment

      All randomized participants who took at least 1 dose of study intervention

      type

      Safety Population

   3. achievements

      1. group Id

         FG000

         num Subjects

         126

      2. group Id

         FG001

         num Subjects

         68

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         92

      2. group Id

         FG001

         num Subjects

         39

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

The results presented are based on the data cut-off date of 22 April 2025. Those participants still benefiting from study drug in the opinion of their treating physician continue to receive study drug in Post Analysis Continued Treatment (PACT) phase and their safety data will be reported after they stop receiving treatment as per protocol

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice